Abstract. Background: ASC63 is an oral small molecule programmed cell death-ligand 1 (PD-L1) inhibitor. After oral dosing, ASC63 is rapidly absorbed and converted to its pharmacologically active ...

Cancer cells exhibit a characteristic metabolic pattern known as the Warburg effect, which upregulates glycolysis even in aerobic environments. As a result, cancer cells are exposed to an acidic ...

AbstractPurpose:. LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of ...

Endocrine therapy (ET), combined with CDK4/6, mTOR, or PI3K inhibitors, is an effective treatment option for patients with estrogen receptor–positive (ER +)/human epidermal growth factor receptor ...

Our study addresses the urgent need for treatment strategies for TKI-resistant gastrointestinal stromal tumors (GIST). We have identified a non-TKI compound, OPB-171775, that exhibits significant ...

Abstract. Background: The 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), like osimertinib, provide marked clinical benefit for EGFR-mutant non-small cell lung ...

In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA + EV-low and -high groups, ...

RAS is the most frequently mutated oncogene in human cancer.RAS mutations occur in approximately 260,000 new cancer cases per year in the United States and 3.4 million per year worldwide (). RAS genes ...

Insurance giant Cigna accused Bristol Myers Squibb (BMS) of maintaining a monopoly over Pomalyst (pomalidomide), the pharma company’s $2-billion-a-year immunomodulatory drug for multiple myeloma. In a ...

Single-cell analyses reveal ductal carcinoma in situ comprises multiple genetic clones with significant phenotypic diversity and link alterations in epithelial cell states and basement membrane ...

AbstractImmune checkpoint blockers (ICB) targeting the PD-1/PD-L1 axis represent established therapies for many cancers. However, resistance occurs in most patients due to complex immune-suppressive ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...